Latest Research And Development News

Page 5 of 115
Livium delivered its strongest lithium-ion battery collection quarter on record for FY26, lifting first-quarter revenue to A$1.84 million and gross profit to A$0.95 million. But operating cash flow remained negative at A$1.01 million, leaving the recycler with about 3.2 quarters of funding at the September quarter-end rate.
Victor Sage
Victor Sage
30 Oct 2026
Imugene reported an 86% overall response rate in its BTK inhibitor combination cohort, but ended September with only 0.70 quarters of estimated funding at the reported cash burn. The biotechnology company is assessing further capital sources while navigating a leadership transition and convertible note obligations.
Ada Torres
Ada Torres
30 Oct 2026
Red Metal is advancing a pre-feasibility study for a potential 20 Mtpa heap leach operation at Sybella, backed by encouraging Fresh Granite test work and a 5,000 metre drilling program. The company ended September with A$3.031 million in cash, equivalent to an estimated 1.9 quarters of funding at the current operating cash rate.
Maxwell Dee
Maxwell Dee
30 Oct 2026
HITIQ has expanded its military research ambitions and added fresh funding during the September quarter, but the company ended the period with $658,242 in cash and estimated funding for only one quarter. Its US collaboration remains non-binding, leaving financing and commercial execution as the immediate tests.
Victor Sage
Victor Sage
30 Oct 2026
Nanollose has narrowed its microbial cellulose scale-up plan to one company-controlled Western Australian pilot facility, with all Stage 1 equipment ordered and paid for. The progress comes with a clear funding constraint: the ASX-listed biomaterials developer ended September with $758,000 in cash, equivalent to 1.41 quarters of funding at its current operating burn.
Victor Sage
Victor Sage
30 Oct 2026
OncoSil Medical enters FY27 with FDA approval for its cancer device, rising quarterly revenue and fresh institutional funding, but its U.S. opportunity still depends on reimbursement and a tightly controlled initial rollout. Cash rose to A$8.7 million after the capital raise, while operating cash use remained substantial.
Victor Sage
Victor Sage
30 Oct 2026
Iondrive’s updated model points to a US$243 million post-tax NPV for its proposed Oklahoma rare earth module, but the headline economics now face their first substantial bulk-scale test. The company is targeting 1.4 tonnes of mixed rare earth oxides from a North American qualification campaign while pursuing debt, grants and incentives.
Victor Sage
Victor Sage
30 Oct 2026
Nexalis Therapeutics ended September with $371,000 in cash, equivalent to just 0.9 quarters of funding at its recent operating burn. The company has settled its dispute with Linlithgow Family Office, but its clinical programs remain paused while it pursues R&D tax funding and a new capital raise.
Ada Torres
Ada Torres
30 Oct 2026
Algorae Pharmaceuticals has moved closer to its first expected NSW Health supply orders while reporting stronger preclinical results from its AOS2 drug-discovery platform. The company ended September with $3.15 million in cash and a further $3 million undrawn facility, but its commercial contract carries no minimum volume commitment.
Victor Sage
Victor Sage
30 Oct 2026
Optiscan has moved its InForm and InVue medical-imaging devices into formal US FDA review after a quarter of intensive regulatory and clinical work. The milestone comes with $11.093 million in cash and a reported 3.5 quarters of funding at the latest operating burn rate.
Victor Sage
Victor Sage
30 Oct 2026
TALi Digital closed its September quarter with $3.9 million in cash after completing a $3.3 million capital raise and winning shareholder approval for the Datasphere transaction. The company has also exercised an option to negotiate exclusive worldwide rights to Technion in-memory computing technology, although the licence remains unsigned and the technology unproven at commercial scale.
Victor Sage
Victor Sage
30 Oct 2026
Clever Culture Systems has started FY27 with three APAS Independence sales to Novo Nordisk and AstraZeneca, while targeting eight first-half sales and evaluations. The sales momentum comes with $1.6 million of unsecured loans due in December and a proposed extension still to be secured.
Victor Sage
Victor Sage
30 Oct 2026

Browse the archive

Full archive